Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and ribociclib

sorafenib has been researched along with ribociclib in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(ribociclib)		Trials
(ribociclib)		Recent Studies (post-2010) (ribociclib)
6,5207305,25133056322

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ribociclib (IC50)
Cyclin-T1Homo sapiens (human)1.1228
Cyclin-dependent kinase 4Homo sapiens (human)0.0156
G1/S-specific cyclin-D1Homo sapiens (human)0.0235
G1/S-specific cyclin-D3Homo sapiens (human)0.0352
Cyclin-dependent kinase 9Homo sapiens (human)1.1228
Cyclin-dependent kinase 6Homo sapiens (human)0.0393

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z1
De Toni, EN; Denk, G; Gerbes, AL; Hohenester, S; Itzel, T; Mayerle, J; Munker, S; Ofner, A; Reiter, FP; Schiergens, TS; Spampatti, M; Teufel, A; Wimmer, R; Ye, L; Ziesch, A1

Reviews

1 review(s) available for sorafenib and ribociclib

ArticleYear
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors

2019

Other Studies

2 other study(ies) available for sorafenib and ribociclib

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Cellular oncology (Dordrecht), 2019, Volume: 42, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Hepatocytes; Humans; Liver Neoplasms; Purines; Retinoblastoma Protein; RNA, Small Interfering; Sorafenib

2019